Bayer submits low-dose gadolinium contrast agent for FDA approval
Bayer has submitted a New Drug Application to the US Food and Drug Administration for gadoquatrane, its investigational low-dose gadolinium-based contrast agent (GBCA) for contrast-enhanced magnetic resonance imaging of the central nervous system and other body regions. The submission covers use in adults and paediatric patients, including term neonates.
